Healthcare Industry News: Medivation
News Release - January 3, 2017
Graybug Vision Appoints Thomas S. Templeman, PhD, as Chief Operating OfficerREDWOOD CITY, CA--(Healthcare Sales & Marketing Network) - Graybug Vision, Inc., a venture-stage pharmaceutical company committed to developing potentially transformative therapies for ocular diseases including wet age-related macular degeneration (AMD) and glaucoma, said today that Thomas S. Templeman, PhD, has joined the company as Chief Operating Officer. In this new position, Dr. Templeman reports to Graybug Vision Chief Executive Officer Jeffrey L. Cleland, PhD, and will lead process development, manufacturing, quality and program management.
"Tom has deep knowledge of pharmaceutical drug development, strong business expertise and grasp of the healthcare landscape, with expertise in biological, small molecules and combination products," commented Dr. Cleland. "We are fortunate to have him join our senior management team now, as GB-102, our lead product for twice per year injections to treat patients with neovascular (wet) AMD, will enter clinical trials in the second half of this year."
Thomas S. Templeman, PhD, said, "There is a dramatic increase in eye diseases due to our aging population, and an increased need for new and more effective treatments. Graybug Vision's novel delivery technology, to create injectable, long-acting products to deliver single or multiple drugs for up to one year in the eye, significantly reduces the treatment burden on patients and physicians. I am excited to join the management team with our efforts to deliver innovative care to patients."
Dr. Templeman began his career as a research and development scientist and over the past two decades has held management positions at, among others: Ortho Diagnostic Products and Centocor Biologics; Liquidia Technologies, where he was Senior Vice President, Integrated Supply Chain; and at Hospira, where he was Vice President, Manufacturing, Science & Technology. He received his BS in Biology from The University of Santa Clara and his PhD in Biological Sciences from Dartmouth College and completed an NIH Postdoctoral Fellowship at Harvard University.
About Graybug Vision
Graybug Vision is developing novel products for the treatment of people with ocular diseases. The company's proprietary injectable products are designed to enable less frequent administration and to reduce the burden of treatment for patients with ocular diseases. The company's lead product, GB-102, has the potential for twice per year injections to treat patients with neovascular (wet) AMD. Graybug Vision has developed a library of compounds to treat glaucoma by lowering intraocular pressure alone or in combination with neuroprotection when injected twice per year into the subconjunctiva. For more information, please visit www.graybug.com.
Source: Graybug Vision
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.